[EN] BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS RELIÉS PAR UN PONT EN TANT QU'INHIBITEURS DE L'INTÉGRASE DU VIH
申请人:MERCK SHARP & DOHME
公开号:WO2010088167A1
公开(公告)日:2010-08-05
Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, χ3, Y, Z, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
化合物I的公式是HIV整合酶抑制剂和HIV复制抑制剂:Q中的星号*表示与化合物其余部分的连接点;n、L1、L2、X1、X2、χ3、Y、Z、R1、R2和R3在此定义。这些化合物对于预防或治疗HIV感染以及预防、治疗或延缓艾滋病的发病或进展是有用的。这些化合物可用作抗HIV感染和艾滋病的化合物本身(或其水合物或溶剂化合物)或以药学上可接受的盐的形式。这些化合物及其盐可用作药物组合物的成分,可选择地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。